Cargando…

Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia

INTRODUCTION: Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for disease modeling. However, it is not invariably successful to recapitulate the disease phenotype because of the immaturity of hiPSC-derived cardiomyocytes (hiPSC-CMs). The purpose of this study was to establis...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Kenichi, Makiyama, Takeru, Yoshida, Yoshinori, Wuriyanghai, Yimin, Kamakura, Tsukasa, Nishiuchi, Suguru, Hayano, Mamoru, Harita, Takeshi, Yamamoto, Yuta, Kohjitani, Hirohiko, Hirose, Sayako, Chen, Jiarong, Kawamura, Mihoko, Ohno, Seiko, Itoh, Hideki, Takeuchi, Ayako, Matsuoka, Satoshi, Miura, Masaru, Sumitomo, Naokata, Horie, Minoru, Yamanaka, Shinya, Kimura, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072719/
https://www.ncbi.nlm.nih.gov/pubmed/27764147
http://dx.doi.org/10.1371/journal.pone.0164795
_version_ 1782461449287761920
author Sasaki, Kenichi
Makiyama, Takeru
Yoshida, Yoshinori
Wuriyanghai, Yimin
Kamakura, Tsukasa
Nishiuchi, Suguru
Hayano, Mamoru
Harita, Takeshi
Yamamoto, Yuta
Kohjitani, Hirohiko
Hirose, Sayako
Chen, Jiarong
Kawamura, Mihoko
Ohno, Seiko
Itoh, Hideki
Takeuchi, Ayako
Matsuoka, Satoshi
Miura, Masaru
Sumitomo, Naokata
Horie, Minoru
Yamanaka, Shinya
Kimura, Takeshi
author_facet Sasaki, Kenichi
Makiyama, Takeru
Yoshida, Yoshinori
Wuriyanghai, Yimin
Kamakura, Tsukasa
Nishiuchi, Suguru
Hayano, Mamoru
Harita, Takeshi
Yamamoto, Yuta
Kohjitani, Hirohiko
Hirose, Sayako
Chen, Jiarong
Kawamura, Mihoko
Ohno, Seiko
Itoh, Hideki
Takeuchi, Ayako
Matsuoka, Satoshi
Miura, Masaru
Sumitomo, Naokata
Horie, Minoru
Yamanaka, Shinya
Kimura, Takeshi
author_sort Sasaki, Kenichi
collection PubMed
description INTRODUCTION: Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for disease modeling. However, it is not invariably successful to recapitulate the disease phenotype because of the immaturity of hiPSC-derived cardiomyocytes (hiPSC-CMs). The purpose of this study was to establish and analyze iPSC-based model of catecholaminergic polymorphic ventricular tachycardia (CPVT), which is characterized by adrenergically mediated lethal arrhythmias, more precisely using electrical pacing that could promote the development of new pharmacotherapies. METHOD AND RESULTS: We generated hiPSCs from a 37-year-old CPVT patient and differentiated them into cardiomyocytes. Under spontaneous beating conditions, no significant difference was found in the timing irregularity of spontaneous Ca(2+) transients between control- and CPVT-hiPSC-CMs. Using Ca(2+) imaging at 1 Hz electrical field stimulation, isoproterenol induced an abnormal diastolic Ca(2+) increase more frequently in CPVT- than in control-hiPSC-CMs (control 12% vs. CPVT 43%, p<0.05). Action potential recordings of spontaneous beating hiPSC-CMs revealed no significant difference in the frequency of delayed afterdepolarizations (DADs) between control and CPVT cells. After isoproterenol application with pacing at 1 Hz, 87.5% of CPVT-hiPSC-CMs developed DADs, compared to 30% of control-hiPSC-CMs (p<0.05). Pre-incubation with 10 μM S107, which stabilizes the closed state of the ryanodine receptor 2, significantly decreased the percentage of CPVT-hiPSC-CMs presenting DADs to 25% (p<0.05). CONCLUSIONS: We recapitulated the electrophysiological features of CPVT-derived hiPSC-CMs using electrical pacing. The development of DADs in the presence of isoproterenol was significantly suppressed by S107. Our model provides a promising platform to study disease mechanisms and screen drugs.
format Online
Article
Text
id pubmed-5072719
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50727192016-10-27 Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia Sasaki, Kenichi Makiyama, Takeru Yoshida, Yoshinori Wuriyanghai, Yimin Kamakura, Tsukasa Nishiuchi, Suguru Hayano, Mamoru Harita, Takeshi Yamamoto, Yuta Kohjitani, Hirohiko Hirose, Sayako Chen, Jiarong Kawamura, Mihoko Ohno, Seiko Itoh, Hideki Takeuchi, Ayako Matsuoka, Satoshi Miura, Masaru Sumitomo, Naokata Horie, Minoru Yamanaka, Shinya Kimura, Takeshi PLoS One Research Article INTRODUCTION: Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for disease modeling. However, it is not invariably successful to recapitulate the disease phenotype because of the immaturity of hiPSC-derived cardiomyocytes (hiPSC-CMs). The purpose of this study was to establish and analyze iPSC-based model of catecholaminergic polymorphic ventricular tachycardia (CPVT), which is characterized by adrenergically mediated lethal arrhythmias, more precisely using electrical pacing that could promote the development of new pharmacotherapies. METHOD AND RESULTS: We generated hiPSCs from a 37-year-old CPVT patient and differentiated them into cardiomyocytes. Under spontaneous beating conditions, no significant difference was found in the timing irregularity of spontaneous Ca(2+) transients between control- and CPVT-hiPSC-CMs. Using Ca(2+) imaging at 1 Hz electrical field stimulation, isoproterenol induced an abnormal diastolic Ca(2+) increase more frequently in CPVT- than in control-hiPSC-CMs (control 12% vs. CPVT 43%, p<0.05). Action potential recordings of spontaneous beating hiPSC-CMs revealed no significant difference in the frequency of delayed afterdepolarizations (DADs) between control and CPVT cells. After isoproterenol application with pacing at 1 Hz, 87.5% of CPVT-hiPSC-CMs developed DADs, compared to 30% of control-hiPSC-CMs (p<0.05). Pre-incubation with 10 μM S107, which stabilizes the closed state of the ryanodine receptor 2, significantly decreased the percentage of CPVT-hiPSC-CMs presenting DADs to 25% (p<0.05). CONCLUSIONS: We recapitulated the electrophysiological features of CPVT-derived hiPSC-CMs using electrical pacing. The development of DADs in the presence of isoproterenol was significantly suppressed by S107. Our model provides a promising platform to study disease mechanisms and screen drugs. Public Library of Science 2016-10-20 /pmc/articles/PMC5072719/ /pubmed/27764147 http://dx.doi.org/10.1371/journal.pone.0164795 Text en © 2016 Sasaki et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sasaki, Kenichi
Makiyama, Takeru
Yoshida, Yoshinori
Wuriyanghai, Yimin
Kamakura, Tsukasa
Nishiuchi, Suguru
Hayano, Mamoru
Harita, Takeshi
Yamamoto, Yuta
Kohjitani, Hirohiko
Hirose, Sayako
Chen, Jiarong
Kawamura, Mihoko
Ohno, Seiko
Itoh, Hideki
Takeuchi, Ayako
Matsuoka, Satoshi
Miura, Masaru
Sumitomo, Naokata
Horie, Minoru
Yamanaka, Shinya
Kimura, Takeshi
Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title_full Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title_fullStr Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title_full_unstemmed Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title_short Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia
title_sort patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates s107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072719/
https://www.ncbi.nlm.nih.gov/pubmed/27764147
http://dx.doi.org/10.1371/journal.pone.0164795
work_keys_str_mv AT sasakikenichi patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT makiyamatakeru patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT yoshidayoshinori patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT wuriyanghaiyimin patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT kamakuratsukasa patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT nishiuchisuguru patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT hayanomamoru patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT haritatakeshi patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT yamamotoyuta patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT kohjitanihirohiko patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT hirosesayako patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT chenjiarong patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT kawamuramihoko patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT ohnoseiko patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT itohhideki patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT takeuchiayako patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT matsuokasatoshi patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT miuramasaru patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT sumitomonaokata patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT horieminoru patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT yamanakashinya patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia
AT kimuratakeshi patientspecifichumaninducedpluripotentstemcellmodelassessedwithelectricalpacingvalidatess107asapotentialtherapeuticagentforcatecholaminergicpolymorphicventriculartachycardia